Revisions to the Filing Process for Commission Forms, 5968 [C1-2019-00460]
Download as PDF
<![CDATA[
5968
Federal Register / Vol. 84, No. 37 / Monday, February 25, 2019 / Proposed Rules
AD: If any service information contains
procedures or tests that are identified as RC,
those procedures and tests must be done to
comply with this AD; any procedures or tests
that are not identified as RC are
recommended. Those procedures and tests
that are not identified as RC may be deviated
from using accepted methods in accordance
with the operator’s maintenance or
inspection program without obtaining
approval of an AMOC, provided the
procedures and tests identified as RC can be
done and the airplane can be put back in an
airworthy condition. Any substitutions or
changes to procedures or tests identified as
RC require approval of an AMOC.
(x) Related Information
(1) Refer to Mandatory Continuing
Airworthiness Information (MCAI) EASA AD
2018–0135, dated June 26, 2018, for related
information. This MCAI may be found in the
AD docket on the internet at https://
www.regulations.gov by searching for and
locating Docket No. FAA–2019–0017.
(2) For more information about this AD,
contact Sanjay Ralhan, Aerospace Engineer,
International Section, Transport Standards
Branch, FAA, 2200 South 216th St., Des
Moines, WA 98198; telephone and fax 206–
231–3223.
(3) For service information identified in
this AD, contact Airbus SAS, Airworthiness
Office—EIAS, Rond-Point Emile Dewoitine
No: 2, 31700 Blagnac Cedex, France;
telephone +33 5 61 93 36 96; fax +33 5 61
93 44 51; email account.airworth-eas@
airbus.com; internet https://www.airbus.com.
You may view this service information at the
FAA, Transport Standards Branch, 2200
South 216th St., Des Moines, WA. For
information on the availability of this
material at the FAA, call 206–231–3195.
[FR Doc. C1–2019–00460 Filed 2–22–19; 8:45 am]
BILLING CODE 1301–00–D
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 50, 312, and 812
[Docket No. FDA–2018–N–2727]
RIN 0910–AH52
Institutional Review Board Waiver or
Alteration of Informed Consent for
Minimal Risk Clinical Investigations;
Reopening of Comment Period
AGENCY:
Food and Drug Administration,
HHS.
Proposed rule; reopening of
comment period.
ACTION:
Correction
The Food and Drug
Administration (FDA or the Agency) is
reopening the comment period for the
proposed rule that appeared in the
Federal Register of November 15, 2018.
In the Federal Register of December 20,
2018, the Agency extended the
comment period until February 13,
2019. The Agency is taking this action
to reopen the comment period to allow
interested persons additional time to
submit comments due to technical
issues with the Federal eRulemaking
Portal (https://www.regulations.gov) on
February 13, 2019.
DATES: FDA is reopening the comment
period on the proposed rule published
November 15, 2018 (83 FR 57378).
Submit either electronic or written
comments by March 7, 2019.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before March 7,
2019. The https://www.regulations.gov
electronic filing system will accept
comments until 11:59 p.m. Eastern Time
at the end of March 7, 2019. Comments
received by mail/hand delivery/courier
(for written/paper submissions) will be
considered timely if they are
postmarked or the delivery service
acceptance receipt is on or before that
date.
In proposed rule document 2019–
00460 beginning on page 1412 in the
issue of Monday, February 4, 2019,
make the following correction:
On page 1416, in the second column,
the last line of text should read as
follows:
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
Issued in Des Moines, Washington, on
February 1, 2019.
Michael Kaszycki,
Acting Director, System Oversight Division,
Aircraft Certification Service.
[FR Doc. 2019–02929 Filed 2–22–19; 8:45 am]
BILLING CODE 4910–13–P
DEPARTMENT OF ENERGY
Federal Energy Regulatory
Commission
18 CFR Parts 141 and 385
[Docket No. RM19–12–000]
Revisions to the Filing Process for
Commission Forms
amozie on DSK3GDR082PROD with PROPOSALS1
‘‘ b 100 hours to prepare and submit
the first filing using XBRL; and’’.
VerDate Sep<11>2014
16:08 Feb 22, 2019
Jkt 247001
SUMMARY:
PO 00000
Frm 00012
Fmt 4702
Sfmt 4702
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2018–N–2727 for ‘‘Institutional Review
Board Waiver or Alteration of Informed
Consent for Minimal Risk Clinical
Investigations.’’ Received comments,
those filed in a timely manner (see
ADDRESSES), will be placed in the docket
and, except for those submitted as
‘‘Confidential Submissions,’’ publicly
viewable at https://www.regulations.gov
or at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
E:\FR\FM\25FEP1.SGM
25FEP1
]]>Agencies
[Federal Register Volume 84, Number 37 (Monday, February 25, 2019)]
[Proposed Rules]
[Page 5968]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: C1-2019-00460]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF ENERGY
Federal Energy Regulatory Commission
18 CFR Parts 141 and 385
[Docket No. RM19-12-000]
Revisions to the Filing Process for Commission Forms
Correction
In proposed rule document 2019-00460 beginning on page 1412 in the
issue of Monday, February 4, 2019, make the following correction:
On page 1416, in the second column, the last line of text should
read as follows:
`` [ballot] 100 hours to prepare and submit the first filing using
XBRL; and''.
[FR Doc. C1-2019-00460 Filed 2-22-19; 8:45 am]
BILLING CODE 1301-00-D
